Literature DB >> 15879679

Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium.

Tomoyuki Matsuda1, Kentaro Takeda, Mie Ito, Reiko Yamagishi, Miku Tamura, Hideki Nakamura, Noriko Tsuruoka, Tomoaki Saito, Haruko Masumiya, Takeshi Suzuki, Naoko Iida-Tanaka, Maho Itokawa-Matsuda, Toru Yamashita, Nobutomo Tsuruzoe, Hikaru Tanaka, Koki Shigenobu.   

Abstract

NIP-142 is a novel benzopyran compound that was shown to prolong the atrial effective refractory period and terminate experimental atrial fibrillation in the dog. In the present study, we examined the effects of NIP-142 on isolated guinea pig myocardium and on the G-protein-coupled inwardly rectifying potassium channel current (acetylcholine-activated potassium current; I(KACh)) expressed in Xenopus oocytes. NIP-142 (10 and 100 microM) concentration-dependently prolonged the refractory period and action potential duration in the atrium but not in the ventricle. E-4031 and 4-aminopyridine prolonged action potential duration in both left atrium and right ventricle. Prolongation by NIP-142 of the atrial action potential duration was observed at stimulation frequencies between 0.5 and 5 Hz. In contrast, the prolongation by E-4031 was not observed at higher frequencies. Tertiapin, a blocker of I(KACh), prolonged action potential duration in the atrium but not in the ventricle. NIP-142 completely reversed the carbachol-induced shortening of atrial action potential duration. NIP-142 (1 to 100 microM), as well as tertiapin (0.1 to 100 nM), concentration-dependently blocked I(KACh) expressed in Xenopus oocytes; the blockade by NIP-142 was not affected by membrane voltage. In conclusion, NIP-142 was shown to prolong atrial refractory period and action potential duration through blockade of I(KACh) which may possibly explain its previously described antiarrhythmic activity. NIP-142 has pharmacological properties that are different from classical class III antiarrhythmic agents such as atria specificity and lack of reverse frequency dependence, and thus appears promising for the treatment of supraventricular arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15879679     DOI: 10.1254/jphs.fpj04045x

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  6 in total

Review 1.  [New antiarrhythmic drugs for therapy of atrial fibrillation: I. Ion channel blockers].

Authors:  U Ravens; E Wettwer; U Schotten; R Wessel; D Dobrev
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2006-06

Review 2.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

3.  How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  J Atr Fibrillation       Date:  2008

Review 4.  New pharmacological strategies for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

5.  Can inhibition of IKur promote atrial fibrillation?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2008-08-06       Impact factor: 6.343

6.  Simultaneous activation of the small conductance calcium-activated potassium current by acetylcholine and inhibition of sodium current by ajmaline cause J-wave syndrome in Langendorff-perfused rabbit ventricles.

Authors:  Yu-Dong Fei; Mu Chen; Shuai Guo; Akira Ueoka; Zhenhui Chen; Michael Rubart-von der Lohe; Thomas H Everett; Zhilin Qu; James N Weiss; Peng-Sheng Chen
Journal:  Heart Rhythm       Date:  2020-08-04       Impact factor: 6.343

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.